UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 6-K
_______________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 Under
the Securities Exchange Act of 1934
Date of Report: September 15, 2020
Commission File Number: 001-39365
Amryt Pharma plc
(Exact Name of registrant as specified in its charter)
Dept 920a 196 High Road, Wood Green,
London, United Kingdom, N22 8HH
(Address of principal executive office)
_______________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____
Exhibits
The following document, which is attached as an exhibit hereto, is incorporated by reference herein.
Exhibit | Title | |
Press release, dated September 15, 2020 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Amryt Pharma plc | ||
(registrant) | ||
Date: September 15, 2020 | By: | /s/ Rory Nealon |
Rory Nealon | ||
Chief Financial Officer |